

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	TON NO. FILING DATE FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.			
09/539,834	03/31/00	SIEGEL	•	• т	00632649		
_			, ¬	EXAMINER			
		QM12/0	412				
ROBERT J DEPKE				TAWELI	TAWEIK.S		
MAYER BROWN & PLATT				ART UNIT	PAPER NUMBER		
PO BOX 2828					1		
CHICAGO IL 60690-2828				3721			
				DATE MAILED):		
					04/12/01		

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

· · · · · · · · · · · · · · · · · · ·		Application No.		Applicant(s)							
• •	Office Action Summary	09/539,834		SIEGEL ET AL.							
•	Office Action Summary	Examiner		Art Unit							
		Sameh H. Tawfik		3721							
The MAILING DATE of this communication appears on the cover sheet with the correspondence address											
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status											
1)⊠	Responsive to communication(s) filed on 31 M	<i>March_2000</i> .									
2a)□	This action is FINAL . 2b)⊠ Thi	is action is non-fir	nal.								
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.										
Dispositi	on of Claims										
4)⊠ Claim(s) <u>1-6</u> is/are pending in the application.											
4a) Of the above claim(s) is/are withdrawn from consideration.											
5) Claim(s) is/are allowed.											
6)⊠ Claim(s) <u>1-6</u> is/are rejected.											
7)	7) Claim(s) is/are objected to.										
8) Claims are subject to restriction and/or election requirement.											
Application	on Papers										
9)⊠ The specification is objected to by the Examiner.											
10) The drawing(s) filed on is/are objected to by the Examiner.											
11) The proposed drawing correction filed on is: a) approved b) disapproved.											
12) The oath or declaration is objected to by the Examiner.											
Priority u	nder 35 U.S.C. § 119										
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).											
a) All b) Some * c) None of:											
1.☐ Certified copies of the priority documents have been received.											
2. Certified copies of the priority documents have been received in Application No.											
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).											
* See the attached detailed Office action for a list of the certified copies not received.											
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).											
Attachment	(s)										
15) 🔀 Notic 16) 🔲 Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	18) [19) [20) [y (PTO-413) Paper l Patent Application (l							

Application/Control Number: 09/539,834

Art Unit: 3721

DETAILED ACTION

Oath/Declaration

It does not identify the citizenship of each inventor. Appropriate correction is required.

Specification

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. For example "Method of filling solid pharmaceutical product packaging".

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Knudsen (4,490,963) in view of Bouthiette (6,023,916).

Knudsen discloses a method of filling solid pharmaceutical product packaging comprising the steps of dispensing one or more solid pharmaceutical products (Fig. 1; via loading station 16) from a plurality of different drug sources (Figs. 4-6 and 12) into each cavity of a plurality of product package cavities (Figs. 1 and 12; via forming station 14); and transferring the solid pharmaceuticals located in the product package cavities into a product package member (Fig. 1; via covering strip 4). Knudsen failed to disclose that the product package template cavities corresponding to cavities of a product package member. However, Bouthiette discloses the product package template cavities (Fig. 9, 1" and 3) corresponding to

Application/Control Number: 09/539,834

Art Unit: 3721

cavities of a product package member (Fig. 9, 23 and 27) to ensure correct positioning of the covering sheet over the cavities (column 1, lines 59 and 60) and to make the process faster by avoiding the step of forming cavities on the strip (via forming station 14).

Therefore, it would have been obvious to one with ordinary skill in the art at the time the invention was made to have modified Knudsen's method of filling solid pharmaceutical product packaging by having the product package template cavities corresponding to cavities of a product package member, as suggested by Bouthiette, in order to ensure correct positioning of the covering sheet over the cavities and to make the process faster by avoiding the step of forming cavities on the strip.

Regarding claim 2: Knudsen discloses that during the step of dispensing the solid pharmaceutical products (via lading station 16) simultaneously sealing another pharmaceutical product package (via sealing station 18) that has been previously filled with a variety of solid pharmaceuticals (Fig. 1).

Regarding claims 3 and 4: Knudsen discloses a step of printing information on a pharmaceutical product package (via printing station 12).

Regarding claims 5 and 6: Knudsen failed to disclose a step of dispensing first and second pharmaceuticals into a single template cavity. However, Bouthiette discloses the step of dispensing first and second pharmaceuticals into a single template cavity (Fig. 8) to be administered to a patient whenever the patient has to take the bills together at the same time (column 1, lines 18-22).

Therefore, it would have been obvious to one with ordinary skill in the art at the time the invention was made to have modified Knudsen's method of filling solid pharmaceutical product

Application/Control Number: 09/539,834

Art Unit: 3721

packaging by having the step of dispensing first and second pharmaceuticals into a single template cavity, as suggested by Bouthiette, in order to be administered to a patient whenever the patient has to take the bills together at the same time.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Naqui et al. (5753456), Thompson et al. (5358118), Rebne et al. (5019125), Harrison et al. (4844246), Haraguchi (4733362), Braverman et al. (4416375), and Braverman (3780856) disclose different method and apparatus for filling pharmaceutical product packaging.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sameh H. Tawfik whose telephone number is (703) 308-2809. The examiner can normally be reached on Monday - Friday from 8:00 AM to 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Vo can be reached on (703) 308-1789. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3579 for regular communications and (703) 308-7769 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1148.

ST March 27, 2001

> PETER VO UPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700